Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in
Wuhan, China and spread rapidly. Recent studies have found that⁓ 15.7% of patients …

In December 2019, a novel coronavirus pneumonia (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly broke out in China and rapidly …

Background Severe acute respiratory syndrome Coronavirus-2 invades the cells via ACE2
receptor and damages multiple organs of the human body. Understanding the pathological …

Purpose Through the method of network pharmacology, the active components and targets
of Shenqi Wan (SQW) were excavated, the relationship with novel Coronavirus pneumonia …

Mounting evidence has shown that single-targeted therapy might be inadequate to achieve
satisfactory effects. Thus, drug combinations are gaining attention as they can regulate …

The first reported case of coronavirus disease 2019 (COVID‐19) occurred in Wuhan, Hubei,
China. Thereafter, it spread through China and worldwide in only a few months, reaching a …

We recently developed a molecule (GT-73) that blocked leukocyte transendothelial
migration from blood to the peripheral tissues, supposedly by affecting the platelet …

" 疫毒袭肺证" 是北京市中医管理局对新型冠状病毒感染肺炎的中医病证分类,
本研究首次建立了与新型冠状病毒中医寒湿疫毒袭肺证相吻合的病证结合小鼠模型 …

Background: As one of the eight effective traditional Chinese medicines for the treatment of
atypical pneumonia, compound Kushen injection (CKI) played an important role in …

Provided are processes for the prevention or treatment of infection by SARS-CoV-2. Some
aspects provide adminis tration of a sphingoid compound, optionally sphingosine, an active …